Cargando…

BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer

Methylation of the BRCA1 promoter is an epigenetic gene expression regulator and is frequently observed in ovarian cancer; however, conversion of methylation status is thought to drive disease recurrence. Therefore, longitudinal monitoring of methylation status by liquid biopsy in cell‐free DNA may...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elazezy, Maha, Prieske, Katharina, Kluwe, Lan, Oliveira‐Ferrer, Leticia, Peine, Sven, Müller, Volkmar, Woelber, Linn, Schmalfeldt, Barbara, Pantel, Klaus, Joosse, Simon A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637552/ https://www.ncbi.nlm.nih.gov/pubmed/34601813 http://dx.doi.org/10.1002/1878-0261.13108

Ejemplares similares

Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer
por: Prieske, Katharina, et al.
Publicado: (2017)

Detection and Characterization of Estrogen Receptor α Expression of Circulating Tumor Cells as a Prognostic Marker
por: Ningsi, Retno, et al.
Publicado: (2022)

VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients
por: Kuerti, Sascha, et al.
Publicado: (2017)

VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients
por: Ding, Yi, et al.
Publicado: (2022)

Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management
por: Elazezy, Maha, et al.
Publicado: (2018)

Combined Liquid Biopsy Methylation Analysis of CADM1 and MAL in Cervical Cancer Patients
por: Leffers, Markus, et al.
Publicado: (2022)

Emerging Insights into Keratin 16 Expression during Metastatic Progression of Breast Cancer
por: Elazezy, Maha, et al.
Publicado: (2021)

Pre-Analytical and Analytical Variables of Label-Independent Enrichment and Automated Detection of Circulating Tumor Cells in Cancer Patients
por: Koch, Claudia, et al.
Publicado: (2020)

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer
por: Mahner, Sven, et al.
Publicado: (2015)

Transcriptome Analysis in Vulvar Squamous Cell Cancer
por: Prieske, Katharina, et al.
Publicado: (2021)

Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature
por: Woelber, Linn, et al.
Publicado: (2021)

E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer
por: Trillsch, Fabian, et al.
Publicado: (2016)

Comparison of PapilloCheck and Linear Array to Detect and Differentiate Human Papillomaviruses in Cervical and Tonsillar Smears from Females with Cervical Intraepithelial Lesions
por: Grimm, Donata, et al.
Publicado: (2018)

Impact of Introducing a PACU24 Concept on the Perioperative Outcome of Patients with Advanced Ovarian Cancer Treated with Cytoreductive Surgery
por: Reuter, Susanne, et al.
Publicado: (2023)

Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients
por: Babayan, Anna, et al.
Publicado: (2013)

The impact of Enhanced Recovery after Surgery (ERAS) pathways with regard to perioperative outcome in patients with ovarian cancer
por: Reuter, Susanne, et al.
Publicado: (2021)

Exosomal microRNAs as tumor markers in epithelial ovarian cancer
por: Pan, Chi, et al.
Publicado: (2018)

Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives
por: Müller, Volkmar, et al.
Publicado: (2004)

Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients
por: Meng, Xiaodan, et al.
Publicado: (2015)

Biology, detection, and clinical implications of circulating tumor cells
por: Joosse, Simon A, et al.
Publicado: (2015)

Recent translational research: circulating tumor cells in breast cancer patients
por: Müller, Volkmar, et al.
Publicado: (2006)

Breast cancer brain metastases: biology and new clinical perspectives
por: Witzel, Isabell, et al.
Publicado: (2016)

Interplay of lncRNA H19/miR‐675 and lncRNA NEAT1/miR‐204 in breast cancer
por: Müller, Volkmar, et al.
Publicado: (2019)

Pelvic lymphadenectomy in vulvar cancer and its impact on prognosis and outcome
por: Jaeger, A., et al.
Publicado: (2021)

TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients
por: Mahner, Sven, et al.
Publicado: (2010)

Demand for integrative medicine among women with breast and gynecological cancer: a multicenter cross-sectional study in Southern and Northern Germany
por: Grimm, Donata, et al.
Publicado: (2020)

Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma
por: S, Sandeep Kumar, et al.
Publicado: (2019)

Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter hypermethylation
por: de Jong, Vincent M. T., et al.
Publicado: (2022)

Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer
por: Meng, Xiaodan, et al.
Publicado: (2016)

Circulating microRNAs: promising breast cancer biomarkers - authors' response
por: Roth, Carina, et al.
Publicado: (2011)

Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer
por: Roth, Carina, et al.
Publicado: (2010)

Ovarian Cancer-Cell Pericellular Hyaluronan Deposition Negatively Impacts Prognosis of Ovarian Cancer Patients
por: Oliveira-Ferrer, Leticia, et al.
Publicado: (2022)

Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch(®) System and the AdnaTest(®)
por: Gorges, Tobias M., et al.
Publicado: (2016)

Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients
por: Ni, Qingtao, et al.
Publicado: (2018)

Author Correction: Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients
por: Ni, Qingtao, et al.
Publicado: (2019)

Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases
por: Joosse, S A, et al.
Publicado: (2014)

BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases
por: BAI, XUEFENG, et al.
Publicado: (2014)

Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients
por: Gorges, Katharina, et al.
Publicado: (2019)

Circulating Tumour Cell Release after Cement Augmentation of Vertebral Metastases
por: Mohme, Malte, et al.
Publicado: (2017)

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
por: Glodzik, Dominik, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_749tsh7fq9mhm5625567cn4t1q